Es gab 50 kürzliche Insider-Transaktionen für MoonLake Immunotherapeutics (MLTX), darunter 19 Käufe und 31 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $21.58M und die gesamten Insider-Verkäufe auf $61.99M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Bvf Partners L P/il, Santos Da Silva Jorge, Bodenstedt Matthias. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — MLTX
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2026-03-31 |
Bvf Partners L P/il |
10 Percent Owner |
Informierter Verkauf |
248,530 |
$16.79 |
$4.17M |
1,039,238 |
| 2026-01-07 |
Santos Da Silva Jorge |
Chief Executive Officer |
RSU-Zuteilung |
520,342 |
$11.29 |
$5.87M |
520,342 |
| 2026-01-07 |
Bodenstedt Matthias |
Chief Financial Officer |
RSU-Zuteilung |
354,296 |
- |
- |
1,276,305 |
| 2026-01-07 |
Reich Kristian |
Chief Scientific Officer |
RSU-Zuteilung |
520,342 |
$11.29 |
$5.87M |
520,342 |
| 2025-12-19 |
Santos Da Silva Jorge |
Chief Executive Officer |
Aktienrückgabe |
196,316 |
- |
- |
- |
| 2025-12-19 |
Bodenstedt Matthias |
Chief Financial Officer |
Umwandlung (Verkauf) |
8,754 |
- |
- |
- |
| 2025-12-19 |
Reich Kristian |
Chief Scientific Officer |
Aktienrückgabe |
35,389 |
- |
- |
- |
| 2025-12-09 |
Santos Da Silva Jorge |
Chief Executive Officer |
Informierter Verkauf |
70,000 |
$14.49 |
$1.01M |
2,878,577 |
| 2025-12-09 |
Reich Kristian |
Chief Scientific Officer |
Informierter Verkauf |
72,908 |
$14.43 |
$1.05M |
- |
| 2025-12-08 |
Santos Da Silva Jorge |
Chief Executive Officer |
Informierter Verkauf |
130,000 |
$15.08 |
$1.96M |
2,948,577 |
| 2025-12-08 |
Reich Kristian |
Chief Scientific Officer |
Informierter Verkauf |
130,000 |
$15.08 |
$1.96M |
72,908 |
| 2025-10-08 |
Bodenstedt Matthias |
Chief Financial Officer |
Informierter Kauf |
10,870 |
$9.09 |
$98.81K |
627,536 |
| 2025-09-30 |
Chen Bihua |
Other: Former 10% Owner |
Informierter Verkauf |
5,827 |
$6.96 |
$40.56K |
1,994,173 |
| 2025-09-29 |
Chen Bihua |
Other: Former 10% Owner |
Informierter Verkauf |
2,800,000 |
$6.61 |
$18.51M |
2,000,000 |
| 2025-09-02 |
Reich Kristian |
Chief Scientific Officer |
Aktienrückgabe |
48,978 |
- |
- |
35,389 |
| 2025-07-03 |
Moukheibir Catherine |
Director |
Informierter Verkauf |
23,500 |
$48.79 |
$1.15M |
- |
| 2025-06-05 |
Bvf Partners L P/il |
10 Percent Owner |
RSU-Zuteilung |
6,682 |
$48.83 |
$326.28K |
6,682 |
| 2025-06-05 |
Moukheibir Catherine |
Director |
RSU-Zuteilung |
6,682 |
$48.83 |
$326.28K |
6,682 |
| 2025-06-05 |
Loy Spike |
Director |
RSU-Zuteilung |
6,682 |
$48.83 |
$326.28K |
6,682 |
| 2025-06-05 |
Xavier Ramnik |
Director |
RSU-Zuteilung |
6,682 |
$48.83 |
$326.28K |
6,682 |
| 2025-06-05 |
Sturge Simon |
Director |
RSU-Zuteilung |
6,682 |
$48.83 |
$326.28K |
6,682 |
| 2025-06-05 |
Phillips Andrew John |
Director |
RSU-Zuteilung |
6,682 |
$48.83 |
$326.28K |
6,682 |
| 2025-02-27 |
Santos Da Silva Jorge |
Chief Executive Officer |
RSU-Zuteilung |
95,763 |
- |
- |
3,078,577 |
| 2025-02-27 |
Bodenstedt Matthias |
Chief Financial Officer |
RSU-Zuteilung |
95,763 |
- |
- |
616,666 |
| 2025-02-27 |
Reich Kristian |
Chief Scientific Officer |
RSU-Zuteilung |
139,273 |
$41.77 |
$5.82M |
139,273 |
| 2025-01-20 |
Reich Kristian |
Chief Scientific Officer |
Umwandlung (Verkauf) |
1,456 |
- |
- |
1,052 |
| 2025-01-20 |
Reich Kristian |
Chief Scientific Officer |
Umwandlung (Verkauf) |
3,328 |
- |
- |
2,508 |
| 2024-10-04 |
Bvf Partners L P/il |
10 Percent Owner |
Informierter Verkauf |
132,549 |
$50.00 |
$6.63M |
1,287,768 |
| 2024-10-04 |
Sturge Simon |
Director |
Informierter Verkauf |
171,000 |
$53.72 |
$9.19M |
171,980 |
| 2024-06-06 |
Moukheibir Catherine |
Director |
RSU-Zuteilung |
7,688 |
$42.44 |
$326.28K |
7,688 |
| 2024-06-06 |
Loy Spike |
Director |
RSU-Zuteilung |
7,688 |
$42.44 |
$326.28K |
7,688 |
| 2024-06-06 |
Xavier Ramnik |
Director |
RSU-Zuteilung |
7,688 |
$42.44 |
$326.28K |
7,688 |
| 2024-06-06 |
Sturge Simon |
Director |
RSU-Zuteilung |
7,688 |
$42.44 |
$326.28K |
7,688 |
| 2024-06-06 |
Phillips Andrew John |
Director |
RSU-Zuteilung |
7,688 |
$42.44 |
$326.28K |
7,688 |
| 2024-06-06 |
Bvf Partners L P/il |
10 Percent Owner |
RSU-Zuteilung |
7,688 |
$42.44 |
$326.28K |
7,688 |
| 2024-02-29 |
Santos Da Silva Jorge |
Chief Executive Officer |
Informierter Verkauf |
4,740 |
$55.89 |
$264.92K |
2,982,814 |
| 2024-02-28 |
Santos Da Silva Jorge |
Chief Executive Officer |
Informierter Verkauf |
56,065 |
$55.00 |
$3.08M |
2,987,554 |
| 2024-02-28 |
Reich Kristian |
Chief Scientific Officer |
Informierter Verkauf |
28,090 |
$55.00 |
$1.54M |
41,981 |
| 2024-02-27 |
Santos Da Silva Jorge |
Chief Executive Officer |
Informierter Verkauf |
62,810 |
$55.00 |
$3.45M |
3,043,619 |
| 2024-02-27 |
Reich Kristian |
Chief Scientific Officer |
Informierter Verkauf |
29,431 |
$55.00 |
$1.62M |
70,071 |
| 2024-02-21 |
Reich Kristian |
Chief Scientific Officer |
Informierter Verkauf |
569 |
$55.30 |
$31.47K |
99,502 |
| 2024-02-21 |
Santos Da Silva Jorge |
Chief Executive Officer |
Informierter Verkauf |
1,125 |
$55.27 |
$62.18K |
3,106,429 |
| 2024-02-20 |
Santos Da Silva Jorge |
Chief Executive Officer |
Informierter Verkauf |
20,000 |
$57.44 |
$1.15M |
3,107,554 |
| 2024-02-20 |
Reich Kristian |
Chief Scientific Officer |
Informierter Verkauf |
10,000 |
$57.43 |
$574.3K |
100,071 |
| 2024-02-16 |
Reich Kristian |
Chief Scientific Officer |
Informierter Verkauf |
10,000 |
$60.15 |
$601.5K |
110,071 |
| 2024-02-16 |
Santos Da Silva Jorge |
Chief Executive Officer |
Informierter Verkauf |
20,000 |
$60.15 |
$1.2M |
3,127,554 |
| 2024-02-15 |
Reich Kristian |
Chief Scientific Officer |
Informierter Verkauf |
10,000 |
$60.16 |
$601.6K |
120,071 |
| 2024-02-15 |
Santos Da Silva Jorge |
Chief Executive Officer |
Informierter Verkauf |
20,000 |
$60.18 |
$1.2M |
3,147,554 |
| 2024-02-14 |
Reich Kristian |
Chief Scientific Officer |
Informierter Verkauf |
10,000 |
$62.43 |
$624.3K |
130,071 |
| 2023-12-20 |
Bodenstedt Matthias |
Chief Financial Officer |
Informierter Verkauf |
5,264 |
$58.34 |
$307.1K |
520,903 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
